PegIFN-alpha-2a

DRUG2 trials

Sponsors

Janssen Research & Development, LLC

Conditions

Hepatitis B, Chronic

Phase 2

A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection

CompletedNCT04439539

Janssen Research & Development, LLCHepatitis B, Chronic

Start: 2020-09-14End: 2024-02-13Updated: 2025-06-24

A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus Infection

TerminatedNCT05005507

Janssen Research & Development, LLCHepatitis B, Chronic

Start: 2021-11-03End: 2021-12-29Updated: 2024-03-06

Related Papers

Peginterferon alpha-2a add-on to siRNA JNJ-73763989 in untreated patients with HBeAg-positive chronic hepatitis B virus (HBV) infection: the phase 2 REEF-IT study.

2025-11-04